CompletedNot Applicable

Frequent Ketamine Use and Gastrointestinal, Liver and Biliary Sequelae

Hong Kong100 participantsStarted 2014-06

Plain-language summary

30% of ketamine users complain of abdominal discomfort. Long-term ketamine use is associated with hepatotoxicity and pathologic changes to the biliary tract. Yet the prevalence of gastrointestinal and hepatobiliary pathologies in ketamine users has not been well-described. The investigators plan to recruit a large number of ketamine users based on referrals from different Psychiatry clusters in Hong Kong and to investigate the underlying cause of abdominal discomfort, describe the prevalence of different gastrointestinal and hepatobiliary pathologies and describe their long-term outcome.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Use of ketamine or ketamine mixed with other psychotropic drugs with frequency of at least twice per month over 6 months within the last 2 years. * Recurrent abdominal discomfort over the past 3 months or more. * Han Chinese ethnicity. * Age 18-60 years. Exclusion Criteria: * Mental retardation or unable to give informed consent * Co-existing biliary disorders including recurrent pyogenic cholangitis, primary sclerosing cholangitis, IgG4 sclerosing cholangiopathy and HIV cholangiopathy. * Other significant medical co-morbidities

What they're measuring

Incidence of cholangiopathic changes

Timeframe: 3 months

Incidence of peptic ulcer disease

Timeframe: 3 months

Incidence of liver fibrosis

Timeframe: 3 months

Trial details

NCT IDNCT02165488

SponsorThe University of Hong Kong

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-05

View on ClinicalTrials.gov More Gastritis trials